Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 24

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 24
---
 use our patents 
 to prevent others from copying our technology or developing similar technology, or if we   
 cannot obtain a critical license to another’s patent that we need to manufacture and use   
 our equipment, then we would expect our competitive position to weaken.                    |

| ● | Faster                                                                                          
 to Market. Some companies with competitive technologies may move through stages of development, 
 approval, and marketing faster than us. If a competitor receives FDA approval before us,        
 then it will be authorized to sell its products before we can sell ours. Because the first      
 company “to market” often has a significant advantage over others, a second place               
 position could result in less than anticipated sales.                                           |

| ● | Reimbursement                                                                                
 Allowed. In the U.S., third party payers, such as Medicare, may reimburse physicians         
 and hospitals for competitors’ products but not for our own human-use products or reimburse  
 our competitors since they offer less cost or have stronger negotiation position (like large 
 competitors offer for favorable pricing since they sell in larger quantities. This would     
 significantly affect our ability to sell our human-use products in the U.S. and would have   
 a negative impact on revenue and our business as a whole. Outside of the U.S., reimbursement 
 and funding policies vary widely.                                                            |

Risks Related to Protection of Intellectual Property

Our inability to protect our trademarks, patents and trade secrets may prevent us from successfully marketing our products and competing effectively.

Failure to protect our intellectual property could harm our brand and our reputation and adversely affect our ability to compete effectively. Further, enforcing or defending our intellectual property rights, including our licensing rights trademarks, patents, copyrights and trade secrets, could result in the expenditure of significant financial and managerial resources. We regard our intellectual property, particularly our trademarks, patents and trade secrets to be of considerable value and importance to our business and our success. We rely on a combination of trademark, patent, and trade secrecy laws, confidentiality procedures and contractual provisions to protect our intellectual property rights. There can be no assurance that the steps taken by us to protect these proprietary rights will be adequate or that third parties will not infringe or misappropriate our trademarks, patented processes, trade secrets or similar proprietary rights. In addition, there can be no assurance that other parties will not assert infringement claims against us, and we may have to pursue litigation against other parties to assert our rights. Any such claim or litigation could be costly. In addition, any event that would jeopardize our proprietary rights or any claims of infringement by third parties